Concepedia

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study

Miki Horiguchi, Lü Tian, Hajime Uno, Su–Chun Cheng, Dae Hyun Kim, Deborah Schrag, Lee‐Jen Wei

JAMA Oncology · 2018 · 25 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

This study compares conventional hazard ratios and an alternative, clinically interpretable approach to quantify the long-term survival benefit in patients receiving chemotherapy with immunotherapy.

References

6

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · JAMA · 2017 · 893 citations · Full text

, , +13

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Kyongsun Pak, Hajime Uno, Dae Hyun Kim et al. · JAMA Oncology · 2017 · 264 citations · Full text

, , +15

Statistical issues and challenges in immuno-oncology

Tai‐Tsang Chen · Journal for ImmunoTherapy of Cancer · 2013 · 169 citations · Full text

, , +10

Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study

Lihui Zhao, Lü Tian, Hajime Uno et al. · Clinical Trials · 2012 · 90 citations · Full text

, , +16

Designing therapeutic cancer vaccine trials with delayed treatment effect

Zhenzhen Xu, Boguang Zhen, Yongsoek Park et al. · Statistics in Medicine · 2016 · 76 citations

, , +17